Amgen Inc. which can be found using ticker (AMGN) now have 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $322.77 and $170.61 calculating the mean target share price we have $270.96. (at the time of writing). Now with the previous closing price of $313.45 this now indicates there is a potential downside of -13.6%. It’s also worth noting that there is a 50 day moving average of $286.71 while the 200 day moving average is $257.02. The market cap for the company is 168.38B. The current share price for the company is: $314.62 USD
The potential market cap would be $145,553,104,411 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 22.38, revenue per share of $50.16 and a 7.86% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
